Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117- LS-J and 10-1074- LS-J, in Healthy American and African Adults (IAVI C100)
Despite all efforts to increase access to HIV prevention and ART in South Africa, incidence of HIV infection continues to be unacceptably high with an estimated 220 000 new infections per year. There is an urgent need to develop new interventions with a longer duration of action than the currently available pre-exposure prophylaxis (PrEP) which is based on a daily oral regimen. The 3BNC117 and 10-1074 are two of the most potent broadly neutralizing antibodies (bNAbs) available. The combination of these two antibodies, which target two nonoverlapping epitopes on HIV-1 gp 120 provides higher breadth and potency than either antibody alone.
Healthy African adults, ages 18-45 years residing in Johannesburg.
Prof Sinead Delany-Moretlwe, Principal Investigator
Dr Carrie – Ann Matthew Sub-investigator
Dr KimComline Sub-investigator
Dr Jenny Omony Sub-investigator
Dr Nicole Poovan Sub - Investigator
Latest Update: 15 February 2021
For more about C100 please email email@example.com